<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904317</url>
  </required_header>
  <id_info>
    <org_study_id>PV4803-2</org_study_id>
    <nct_id>NCT02904317</nct_id>
  </id_info>
  <brief_title>Misoprostol for Labour Induction</brief_title>
  <official_title>The Misoprostol Vaginal Insert Compared With Oral Misoprostol for Labour Induction in Term Pregnancies: a Pair-matched Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios Kliniken Hamburg GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asklepios Kliniken Hamburg GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare the efficacy and safety of the misoprostol vaginal insert (MVI) with an&#xD;
      off-label use of oral misoprostol (OM).&#xD;
&#xD;
      Design: Pair-matched case-control study.&#xD;
&#xD;
      Setting: Tertiary-care academic centre in Germany.&#xD;
&#xD;
      Population: A cohort of 138 women ≥ 37/0 weeks pregnant undergoing labour induction.&#xD;
&#xD;
      Methods: The induction of labour with a retrievable prostaglandin vaginal insert in a&#xD;
      consecutive series of 69 women was compared with induction using oral misoprostol in a&#xD;
      pair-matched cohort.&#xD;
&#xD;
      Main outcome measures: The primary outcomes were the time from induction to delivery and the&#xD;
      caesarean section rate. Secondary outcomes included uterine tachysystole, tocolysis, fetal&#xD;
      scalp blood testing, meconium-stained amniotic fluid, umbilical arterial pH, and Apgar score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, non-interventional study in a tertiary referral center in Germany N/A The rationale of&#xD;
      our observational study is to describe the efficacy and safety profile of the drug with&#xD;
      definition of active labor according to local clinical practice in a descriptive&#xD;
      observational study in a tertiary referral center.&#xD;
&#xD;
      A time interval from induction of labor to delivery is depending on the duration of the&#xD;
      MISODEL® application. By an observational study the investigators want to describe the&#xD;
      efficacy and safety with regard to time to delivery and complication rate.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      The aim of this study is to describe time to vaginal delivery with definition of active labor&#xD;
      according to local clinical practice.&#xD;
&#xD;
      The time period needed to induce any delivery and to describe the drug safety profile.&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
        -  Time to vaginal delivery in hours in patients with vaginal delivery.&#xD;
&#xD;
        -  Length of time until any delivery&#xD;
&#xD;
        -  Caesarean section rate&#xD;
&#xD;
        -  Time until onset of labor&#xD;
&#xD;
        -  Frequency of vaginal operative delivery&#xD;
&#xD;
        -  Frequency of abnormal CTG (Figo)&#xD;
&#xD;
        -  Frequency of uterine Tachysystole leading to abnormal fetal heartrate i.e. Figo P.&#xD;
           Tachysystole is defined as five or more contractions in 10 minutes averaged over three&#xD;
           consecutive 10-minute periods.&#xD;
&#xD;
        -  Written informed consent of the patients&#xD;
&#xD;
        -  ≥18 years of age&#xD;
&#xD;
        -  Parity five or less with singleton pregnancies&#xD;
&#xD;
        -  ≥36 weeks of gestation&#xD;
&#xD;
        -  Unfavourable cervix (baseline modified Bishop score ≤6)&#xD;
&#xD;
      Misoprostol 200mcg VDS is contraindicated according to the SmPC in the following cases:&#xD;
&#xD;
        -  When there is hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
        -  When labour has started&#xD;
&#xD;
        -  When oxytocic drugs and/or other labour induction agents are being given&#xD;
&#xD;
        -  When there is suspicion or evidence of uterine scar resulting from previous uterine&#xD;
           surgery, e.g. C-section&#xD;
&#xD;
        -  When there is uterine abnormality (e.g. bicornate uterus)&#xD;
&#xD;
        -  When there is placenta praevia or unexplained vaginal bleeding after 24 weeks gestation&#xD;
           with this pregnancy&#xD;
&#xD;
        -  When there is foetal malpresentation&#xD;
&#xD;
        -  When there are signs or symptoms of chorioamnionitis, unless adequate prior treatment&#xD;
           has been instituted&#xD;
&#xD;
        -  Before week 36 of gestation&#xD;
&#xD;
      For evaluation of the primary and secondary endpoints of the study, descriptive statistical&#xD;
      methods will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>time from application of the medication until delivery in minutes</measure>
    <time_frame>September 2015</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants receiving a caesarean section compared to all participants being induced</measure>
    <time_frame>September 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related tachysystole as assessed by cardiotocography</measure>
    <time_frame>September 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events following tocolysis with Partusisten</measure>
    <time_frame>September 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with fetal compromise assessed by the APGAR-Score and the postpartum fetal pH-value</measure>
    <time_frame>September 2015</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">138</enrollment>
  <condition>Labour Induction</condition>
  <arm_group>
    <arm_group_label>Misprostol vaginal insert for labour induction</arm_group_label>
    <description>69 patients matching the inclusion criteria and received MVI for labour induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral misoprostol for labour induction</arm_group_label>
    <description>69 patients matching the inclusion criteria and received OM for labour induction</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort of 138 women ≥ 37/0 weeks pregnant undergoing labour induction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  gynaecologist's indication for induction&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  &gt; 37 weeks of gestation&#xD;
&#xD;
          -  singleton pregnancies&#xD;
&#xD;
          -  cephalic presentation&#xD;
&#xD;
          -  cervical Bishop score of &lt; 5 before priming reassuring fetal heart rate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hypersensitivity to prostaglandins&#xD;
&#xD;
          -  uterine scar&#xD;
&#xD;
          -  parity &gt; 5&#xD;
&#xD;
          -  any contraindication for vaginal delivery&#xD;
&#xD;
          -  cephalopelvic disproportion&#xD;
&#xD;
          -  placenta previa&#xD;
&#xD;
          -  chorioamnionitis&#xD;
&#xD;
          -  antepartum bleeding of unknown aetiology&#xD;
&#xD;
          -  cardiopulmonary, renal, hepatic maternal disease glaucoma&#xD;
&#xD;
          -  fetal congenital abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asklepios Kliniken Hamburg GmbH</investigator_affiliation>
    <investigator_full_name>Peter Schwaerzler</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

